Skip to main
DRTS
DRTS logo

DRTS Stock Forecast & Price Target

DRTS Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Alpha Tau Medical's proprietary Alpha DaRT technology demonstrates the potential to meet a significant unmet need in oncology by harnessing the unique properties of alpha particles for localized radiation therapy. Additionally, there is encouraging evidence suggesting that Alpha DaRT may elicit a systemic response beyond the initially treated area, which could enhance its therapeutic efficacy. Given these promising findings and the company's strong revenue base from Israel, there is a favorable outlook for Alpha Tau Medical's stock as it advances in a competitive oncology market.

Bears say

Alpha Tau Medical Ltd faces several significant risks that contribute to a negative outlook, particularly regarding its proprietary Alpha DaRT technology, which is still in clinical development. The company’s prospects hinge on successful clinical trial outcomes and obtaining regulatory approval in the U.S., both of which remain uncertain. Additionally, challenges related to market size, penetration, competition, and potential dilution risks further complicate the path to commercial success, negatively impacting investor confidence.

DRTS has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alpha Tau Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alpha Tau Medical (DRTS) Forecast

Analysts have given DRTS a Strong Buy based on their latest research and market trends.

According to 1 analysts, DRTS has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alpha Tau Medical (DRTS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.